Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast
Status:
Active, not recruiting
Trial end date:
2021-10-26
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well afimoxifene works in reducing the risk of
breast cancer in women with mammographically dense breast. Estrogen can cause the growth of
breast cancer cells. Hormone therapy using afimoxifene may fight breast cancer by blocking
the use of estrogen by the tumor cells.